Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10‐2474

BACKGROUND AND PURPOSE: In 2016, one person died and four others had mild‐to‐severe neurological symptoms during a phase I trial of the fatty acid amide hydrolase (FAAH) inhibitor BIA 10‐2474. EXPERIMENTAL APPROACH: Pharmacodynamic and pharmacokinetic studies were performed with BIA 10‐2474, PF‐0445...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Pharmacol
Main Authors: Bonifácio, Maria‐João, Sousa, Filipa, Aires, Cátia, Loureiro, Ana I., Fernandes‐Lopes, Carlos, Pires, Nuno M., Palma, Pedro Nuno, Moser, Paul, Soares‐da‐Silva, Patrício
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Research Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7161550/
https://ncbi.nlm.nih.gov/pubmed/31901141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.14973
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados